

Clerk of the House of Representatives  
Legislative Resource Center  
B-106 Cannon Building  
Washington, DC 20515

Secretary of the Senate  
Office of Public Records  
232 Hart Building  
Washington, DC 20510

SECRETARY OF THE  
01 AUG 14 PM 12

# LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant Name <b>The Duberstein Group, Inc.</b>			
2. Registrant Address <input type="checkbox"/> Check if different than previously reported Address <b>2100 Pennsylvania Ave, NW Ste 500</b> City <b>Washington</b> State/Zip (or Country) <b>DC 20037</b> <b>USA</b>			
3. Principal Place of Business (if different from line 2) City _____ State/Zip (or Country) _____			
4. Contact Name <b>John W. Angus, III</b>		Telephone <b>202-728-1100</b>	E-mail (optional) _____
5. Senate ID # <b>12675-253</b>			
7. Client Name <input type="checkbox"/> Self <b>Pharmacia Corporation</b>		6. House ID # <b>31811024</b>	

**TYPE OF REPORT** 8. Year 2001 Midyear (January 1-June 30)  **OR** Year End (July 1-December 31)

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report  >> Termination Date \_\_\_\_\_

11. No Lobbying

## INCOME OR EXPENSES - Complete Either Line 12 OR Line 13

12. Lobbying Firms	13. Organizations
<b>INCOME</b> relating to lobbying activities for this reporting period was: Less than \$10,000 <input type="checkbox"/> \$10,000 or more <input checked="" type="checkbox"/> >> \$ <u>\$40,000.00</u> Income (nearest \$20,000)	<b>EXPENSES</b> relating to lobbying activities for this reporting period were: Less than \$10,000 <input type="checkbox"/> \$10,000 or more <input type="checkbox"/> >> \$ _____ Expenses (nearest \$20,000)
Provide a good faith estimate, rounded to the nearest \$20,000 of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).	<b>14. REPORTING METHOD.</b> Check box to indicate accounting method. See instructions for description of op <input type="checkbox"/> <b>Method A.</b> Reporting amounts using LDA definition <input type="checkbox"/> <b>Method B.</b> Reporting amounts under section 6033(c) the Internal Revenue Code <input type="checkbox"/> <b>Method C.</b> Reporting amounts under section 162(e) Internal Revenue Code

Signature \_\_\_\_\_ Date 8/14/2001



Registrant Name: **The Duberstein Group, Inc.**

Client Name: **Pharmacia Corporation**

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code,** provide information as requested. Attach additional page(s) as needed.

15. General issue area code **MMM** (one per page)

16. Specific Lobbying issues

**S.1135, Medicare Reform Act of 2001, Medicare reform and prescription drug benefit**

**S.357, Medicare Preservation and Improvement Act of 2001, Medicare reform and prescription drug benefit**

**S.358, Medicare Prescription Drug and Modernization Act of 2001, Medicare reform and prescription drug be**

17. House(s) of Congress and Federal agencies contacted

Check if None

**House of Representatives**

**Office of Management and Budget**

**Senate**

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
<b>Angus, III, John W.</b>	
<b>Berman, Michael S.</b>	
<b>Champlin, Steven M.</b>	
<b>Duberstein, Kenneth M.</b>	
<b>Gandy, Henry M.</b>	
<b>Meyer, Daniel</b>	

19. Interest of each foreign entity in the specific issues listed on line 16 above

Check if None

Signature \_\_\_\_\_

Date **8/14/2001**

Printed Name and Title

**John W. Angus, III - Senior Vice President & GC**

Filing #99359cc8-7c66-4fb1-b1dc-712cad2c9693 - Page 3 of 8

Page



Registrant Name: **The Duberstein Group, Inc.**

Client Name: **Pharmacia Corporation**

**LOBBYING ACTIVITY.** Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. **Using a separate page for each code**, provide information as requested. Attach additional page(s) as needed.

15. General issue area code **PHA** (one per page)

16. Specific Lobbying issues

**H.R.2315, Patients' Bill of Rights Act of 2001, Patients' bill of rights**

**H.R.2330, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriat 2002, Reimportation of US drugs from abroad**

**H.R.526, Bipartisan Patient Protection Act of 2001, Patients' bill of rights**

**H.R.946, North American Prescription Price Equity Act of 2001, Reimportation of US drugs from abroad**

**S.1052, Bipartisan Patient Protection Act, Patients' bill of rights**

**S.283, Bipartisan Patient Protection Act of 2001, Patients' bill of rights**

**S.872, Bipartisan Patient Protection Act, Patients' bill of rights**

**S.889, Bipartisan Patients' Bill of Rights Act of 2001, Patients' bill of rights**

17. House(s) of Congress and Federal agencies contacted

Check if None

**Department of Health & Human Services**

**House of Representatives**

**Senate**


18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
<b>Angus, III, John W.</b>	
<b>Berman, Michael S.</b>	
<b>Champlin, Steven M.</b>	
<b>Duberstein, Kenneth M.</b>	
<b>Gandy, Henry M.</b>	
<b>Meyer, Daniel</b>	

19. Interest of each foreign entity in the specific issues listed on line 16 above

Check if None

Signature



Date **8/14/2001**

Printed Name and Title

**John W. Angus, III - Senior Vice President & GC**

Filing #99359cc8-7c66-4fb1-b1dc-712cad2c9693 - Page 5 of 8

Doc



Registrant Name: **The Duberstein Group, Inc.**

Client Name: **Pharmacia Corporation**

Item	Description	Data
16	Lobbying Issues	<b>EXECUTIVE BRANCH ACTIONS: Stem cell research and Federal funding</b>

